A Phase 1 Study of Single Agent Pexidartinib in Asian Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2017
At a glance
- Drugs Pexidartinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Company
- 17 May 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Jul 2016 Status changed from not yet recruiting to recruiting.
- 14 Apr 2016 New trial record